N-(2-chlorophenyl)pyrimidine-4-carbothioamide | 110513-71-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-chlorophenyl)pyrimidine-4-carbothioamide
• CAS: 110513-71-8
• 化学式: C₁₁H₈ClN₃S
• 分子量: 249.724
• InChiKey: VCRKKPKJAFEIKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-chlorophenyl)pyrimidine-4-carbothioamide 在 potassium carbonate 作用下， 以 丙酮 、 正丁醇 为溶剂， 生成
  参考文献：
  名称：

  Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor

  摘要：

  Tankyrases 1 and 2 are central biotargets in the WNT/beta-catenin signaling and Hippo signaling pathways. We have previously developed tankyrase inhibitors bearing a 1,2,4-triazole moiety and binding predominantly to the adenosine binding site of the tankyrase catalytic domain. Here we describe a systematic structure-guided lead optimization approach of these tankyrase inhibitors. The central 1,2,4-triazole template and trans-cyclobutyl linker of the lead compound 1 were left unchanged, while side-group East, West, and South moieties were altered by introducing different building blocks defined as point mutations. The systematic study provided a novel series of compounds reaching picomolar IC50 inhibition in WNT/beta-catenin signaling cellular reporter assay. The novel optimized lead 13 resolves previous atropisomerism, solubility, and Caco-2 efflux liabilities. 13 shows a favorable ADME profile, including improved Caco-2 permeability and oral bioavailability in mice, and exhibits antiproliferative efficacy in the colon cancer cell line COLO 320DM in vitro.

  DOI：

  10.1021/acs.jmedchem.0c00208
• 作为产物：
  描述：

  邻氯苯胺 在 劳森试剂 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 21.0h， 生成 N-(2-chlorophenyl)pyrimidine-4-carbothioamide
  参考文献：
  名称：

  通过杂交方法发现一系列新颖的坦科聚合酶抑制剂

  摘要：

  使用两个特权子结构的结构指导杂交方法可立即获得一系列新的tankyrase抑制剂。鉴定出的抑制剂16对tankyrase 1和2表现出较高的靶亲和力，其生化和细胞IC 50值分别为29 nM，6.3 nM和19 nM，并且对其他聚ADP-核糖聚合酶的选择性高。鉴定出的抑制剂在小鼠，大鼠和狗中显示出良好的体外ADME活性以及良好的口服生物利用度。该方法的关键是在1,2,4-三唑和苯并咪唑酮部分之间使用适当的连接基，与环己烷和苯基连接基相比，环丁基连接基显示出优异的亲和力。

  DOI：

  10.1021/acs.jmedchem.7b00883

文献信息

• [EN] TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS<br/>[FR] DÉRIVÉS DE TRIAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：OSLO UNIV HOSPITAL HF

  公开号：WO2018118868A1

  公开（公告）日：2018-06-28

  The present invention relates to compounds of formula (I'), tautomers, stereoisomers, and pharmaceutically acceptable salts thereof, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy (I') (wherein: Z represents an optionally substituted, 5- or 6-membered unsaturated heterocyclic group comprising at least one nitrogen atom; L represents a 4-, 5- or 6-membered cycloalkyl group, preferably a cyclobutyl group; each R1 independently represents F, CI, Br, I, C1-3 alkyl, C1-3 haloalkyl (e.g. -CF3), -CN, -OH or -NO2, preferably F, CI, Br or 1, e.g. CI or F; each R2independently represents F, CI, Br, I, C1-3 alkyl, -CN, -OH or -NO2, preferably F, CI, Br, I or -CN, e.g. F or -CN; X represents -NR3- or -0-; R3 represents H or a C1-3 alkyl group (e.g. methyl); n is an integer from 0 to 5, preferably 0 to 3, more preferably 0, 1 or 2, e.g 1; and m is an integer from 0 to 5, preferably 0 to 3, more preferably 0, 1 or 2, e.g. 0 or 1). These compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the WNT pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.

  本发明涉及式(I')的化合物，其互变异构体、立体异构体和药学上可接受的盐，以及其制备方法、含有这种化合物的药物配方以及它们在治疗中的用途(I')（其中：Z代表一个可选择取代的、含有至少一个氮原子的5-或6-成员不饱和杂环基团；L代表一个4-、5-或6-成员的环烷基基团，优选为环丁基基团；每个R1独立地代表F、Cl、Br、I、C1-3烷基、C1-3卤代烷基（例如-CF3）、-CN、-OH或-NO2，优选为F、Cl、Br或I，例如Cl或F；每个R2独立地代表F、Cl、Br、I、C1-3烷基、-CN、-OH或- ，优选为F、Cl、Br、I或-CN，例如F或-CN；X代表-NR3-或-0-；R3代表H或一个C1-3烷基基团（例如甲基）；n是一个从0到5的整数，优选为0到3，更优选为0、1或2，例如1；m是一个从0到5的整数，优选为0到3，更优选为0、1或2，例如0或1）。这些化合物在治疗和/或预防受WNT途径信号过度激活和核β-连环蛋白增加影响的疾病或病症方面具有特殊用途。例如，它们可用于预防和/或延缓肿瘤细胞和转移的增殖，例如结肠癌等癌症。
• WO2019243822A5
  申请人：——

  公开号：WO2019243822A5

  公开（公告）日：2022-06-24
• 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS
  申请人：Oslo Universitetssykehus HF

  公开号：EP3810597A1

  公开（公告）日：2021-04-28
• [EN] 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：UNIV OSLO HF

  公开号：WO2019243822A1

  公开（公告）日：2019-12-26

  The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl). These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.